Passa al contenuto
Merck

Alterations of urinary metabolite profile in model diabetic nephropathy.

Biochemical and biophysical research communications (2014-12-17)
Donald F Stec, Suwan Wang, Cody Stothers, Josh Avance, Deon Denson, Raymond Harris, Paul Voziyan
ABSTRACT

Countering the diabetes pandemic and consequent complications, such as nephropathy, will require better understanding of disease mechanisms and development of new diagnostic methods. Animal models can be versatile tools in studies of diabetic renal disease when model pathology is relevant to human diabetic nephropathy (DN). Diabetic models using endothelial nitric oxide synthase (eNOS) knock-out mice develop major renal lesions characteristic of human disease. However, it is unknown whether they can also reproduce changes in urinary metabolites found in human DN. We employed Type 1 and Type 2 diabetic mouse models of DN, i.e. STZ-eNOS(-/-) C57BLKS and eNOS(-/-) C57BLKS db/db, with the goal of determining changes in urinary metabolite profile using proton nuclear magnetic resonance (NMR). Six urinary metabolites with significantly lower levels in diabetic compared to control mice have been identified. Specifically, major changes were found in metabolites from tricarboxylic acid (TCA) cycle and aromatic amino acid catabolism including 3-indoxyl sulfate, cis-aconitate, 2-oxoisocaproate, N-phenyl-acetylglycine, 4-hydroxyphenyl acetate, and hippurate. Levels of 4-hydroxyphenyl acetic acid and hippuric acid showed the strongest reverse correlation to albumin-to-creatinine ratio (ACR), which is an indicator of renal damage. Importantly, similar changes in urinary hydroxyphenyl acetate and hippurate were previously reported in human renal disease. We demonstrated that STZ-eNOS(-/-) C57BLKS and eNOS(-/-) C57BLKS db/db mouse models can recapitulate changes in urinary metabolome found in human DN and therefore can be useful new tools in metabolomic studies relevant to human pathology.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Glicina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glicina, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Glicina, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
Glicina, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Glycine hydrochloride, ≥99% (HPLC)
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
SAFC
Glicina
Supelco
Glicina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Indoxyl sulfate potassium salt
Sigma-Aldrich
Hippuric acid, 98%
Sigma-Aldrich
Glicina, BioXtra, ≥99% (titration)
Sigma-Aldrich
Glicina, ACS reagent, ≥98.5%
Sigma-Aldrich
Glicina, 99%, FCC
Sigma-Aldrich
Glicina, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
USP
Glicina, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
4-Methyl-2-oxovaleric acid, ≥98.0% (T)
Sigma-Aldrich
Glicina, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Supelco
Creatinine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ippurato di sodio, ≥99%
Sigma-Aldrich
Glycine 1 M solution
Sigma-Aldrich
Sodium 4-methyl-2-oxovalerate, leucine metabolite
Supelco
Glicina, analytical standard, for nitrogen determination according to Kjeldahl method
Glicina, European Pharmacopoeia (EP) Reference Standard
Supelco
Glycine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
Glicina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Glicina, tested according to Ph. Eur.